Concepedia

Jonathan Zalevsky

JZ

45

Publications

4.9K

Citations

26

H-Index

1999

Active since

Affiliations

Nektar Therapeutics (United States)(Current)

The University of Texas MD Anderson Cancer Center

Xencor (United States)

Yale Cancer Center

Providence Portland Medical Center

Jonathan Zalevsky is an author at Nektar Therapeutics (United States) specializing in medicine, immunology, and immunotherapy.

Top concepts

MedicineImmunologyImmunotherapyImmune SurveillanceOncologyTumor ImmunityTumor MicroenvironmentCell BiologyInflammationCancer Research

Publications per year

1999–2024

45

Publications

45

β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2

Kathryn DeFea, Jonathan Zalevsky, Mark S. Thoma et al. · The Journal of Cell Biology · 2000 · 805 citations · Full text

Enhanced antibody half-life improves in vivo activity

Jonathan Zalevsky, Aaron K. Chamberlain, Holly M. Horton et al. · Nature Biotechnology · 2010 · 625 citations · Full text

Antibody Half-life Improves, Immunology, Antibody Screening +5

JNK and Tumor Necrosis Factor-α Mediate Free Fatty Acid-induced Insulin Resistance in 3T3-L1 Adipocytes

Matthew Nguyen, Hiroaki Satoh, Svetlana Favelyukis et al. · Journal of Biological Chemistry · 2005 · 402 citations · Full text

Immunology, Activated Jnk, Insulin Signaling +18

Inactivation of TNF Signaling by Rationally Designed Dominant-Negative TNF Variants

Paul M. Steed, Malú G. Tansey, Jonathan Zalevsky et al. · Science · 2003 · 257 citations

Immunology, Cell Death, Pathology +18

Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)

Adi Diab, Nizar M. Tannir, Salah-Eddine Bentebibel et al. · Cancer Discovery · 2020 · 231 citations · Full text

Rows per page

1–5 of 45